This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novartis Pharma AG, Switzerland.
Reference
Adedokun L, et al. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective. Advances in Therapy : 8 Jan 2016. Available from: URL: http://doi.org/10.1007/s12325-015-0279-0
Rights and permissions
About this article
Cite this article
Ranibizumab better value for money in BRVO. PharmacoEcon Outcomes News 745, 30 (2016). https://doi.org/10.1007/s40274-016-2771-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-2771-4